TG1N.F ARMATA PHARMACEUT.
- Market cap
- EUR 124M
- P/E
- -
- P/B
- 2.39x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is TG1N.F undervalued?
Graham numberThe Graham number of ARMATA PHARMACEUT. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ARMATA PHARMACEUT. fundamental analysis
No fundamental analysis for ARMATA PHARMACEUT. yet.
ARMATA PHARMACEUT. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ARMATA PHARMACEUT.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Ph…
Full company profileARMATA PHARMACEUT. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ARMATA PHARMACEUT. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -23.8M | -36.9M | -40.9M | -42.4M | -31.2M | -35.1M |
| EBITDA | - | -36.0M | -65.4M | -6.85M | -156M | -437M |
| Net Income | -23.2M | -36.9M | -69.0M | -18.9M | -174M | -461M |
| EPS | -0.85 | -1.02 | -1.91 | -0.52 | -4.77 | -13 |
| Balance Sheet | ||||||
| Total Assets | 69.8M | 95.8M | 98.4M | 86.4M | 76.9M | 69.8M |
| Total Liabilities | 44.4M | 59.8M | 130M | 134M | 295M | 381M |
| Shareholders' Equity | 25.4M | 36.1M | -32.1M | -48.0M | -219M | -312M |
| Cash & Short-term Investments | 10.3M | 14.9M | 13.5M | 9.29M | 8.69M | 4.75M |
| Cash Flow | ||||||
| Operating Cash Flow | -23.6M | -32.5M | -47.4M | -37.6M | -25.8M | -23.1M |
| Capital Expenditure | 1.30M | 2.21M | 8.14M | 1.88M | 542K | 252K |
| Free Cash Flow | -24.9M | -34.7M | -55.6M | -39.4M | -26.3M | -23.4M |
| Ratios | ||||||
| ROE | -91.2% | -102.3% | - | - | - | - |
| ROA | -33.2% | -38.5% | -70.2% | -21.9% | -226.1% | -661.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
ARMATA PHARMACEUT. dividends
ARMATA PHARMACEUT. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:14 on May 10, 2019.
Who owns ARMATA PHARMACEUT.
- Insiders 67.64%
- Institutions 13.81%
- Public & others 18.55%
- Shares outstanding 37.2M
- Free float 11.9M
ARMATA PHARMACEUT. company profile
- Company name
- ARMATA PHARMACEUT.
- Ticker
- TG1N.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Fiscal year end
- December
- Address
- 5005 McConnell Avenue, Los Angeles, CA, United States, 90066
- Phone
- 310 665 2928
- Website
- armatapharma.com
About ARMATA PHARMACEUT.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
ARMATA PHARMACEUT. management
5- Dr. Deborah L. Birx M.D.CEO & Director · born 1957
- Mr. David D. HouseChief Financial Officer · born 1984
- Dr. Pierre Kyme Ph.D.Chief Business Officer · born 1978
- Mr. Peter HubbardVice President of Operations
- Ms. Bani Tchekanova Ph.D.Head of Regulatory Strategy & Operations